Center-Authored Papers

Filters: Author is Marzinke, Mark A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, Asiimwe S, Haberer JE, Morton J, Ngure K et al..  2016.  Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.. PLoS medicine. 13(8):e1002099. Abstract
Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Kiweewa FM, Nair G, Mhlanga F et al..  2016.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.. The New England journal of medicine. Abstract
Beigi RH, Noguchi LM, Montgomery E, Biggio J, Hendrix CW, Marzinke MA, Dai JY, Pan J, Ayudhya RKN, Schwartz JL et al..  2016.  A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy.. Journal of the International AIDS Society. 19(1):20990. Abstract
C
Carballo-Diéguez A, Balán IC, Brown W, Giguere R, Dolezal C, Leu C-S, Marzinke MA, Hendrix CW, Piper JM, Richardson BA et al..  2017.  High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.. PloS one. 12(7):e0181607. Abstract
Chen I, Chau G, Wang J, Clarke W, Marzinke MA, Cummings V, Breaud A, Laeyendecker O, Fields SD, Griffith S et al..  2016.  Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061).. PloS one. 11(12):e0167629. Abstract
Chen I, Clarke W, Ou S-S, Marzinke MA, Breaud A, Emel LM, Wang J, Hughes JP, Richardson P, Haley DF et al..  2015.  Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064.. PloS one. 10(10):e0140074. Abstract
Chen BA, Panther L, Marzinke MA, Hendrix CW, Hoesley CJ, van der Straten A, Husnik MJ, Soto-Torres L, Nel A, Johnson S et al..  2015.  Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.. Journal of acquired immune deficiency syndromes (1999). 70(3):242-9. Abstract
Chen I, Connor MB, Clarke W, Marzinke MA, Cummings V, Breaud A, Fogel JM, Laeyendecker O, Fields SD, Donnell D et al..  2015.  Antiretroviral drug use and HIV drug resistance among HIV-infected Black men who have sex with men: HIV Prevention Trials Network 061.. Journal of acquired immune deficiency syndromes (1999). Abstract
Cranston RD, Lama JR, Richardson BA, Carballo-Diéguez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu C-S, Galaska B, Jacobson CE et al..  2016.  MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Abstract
F
Fogel JM, Piwowar-Manning E, Donohue K, Cummings V, Marzinke MA, Clarke W, Breaud A, Fiamma A, Donnell D, Kulich M et al..  2015.  Determination of HIV status in African adults with discordant HIV rapid tests.. Journal of acquired immune deficiency syndromes (1999). Abstract
Fogel JM, Clarke W, Kulich M, Piwowar-Manning E, Breaud A, Olson MT, Marzinke MA, Laeyendecker O, Fiamma A, Donnell D et al..  2016.  Antiretroviral drug use in a cross-sectional population survey in Africa: NIMH Project Accept (HPTN 043).. Journal of acquired immune deficiency syndromes (1999). Abstract
G
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico RK, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH et al..  2017.  Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.. Annals of internal medicine. :1-10. Abstract
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico RK, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH et al..  2016.  PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305).. The Journal of infectious diseases. Abstract
H
Hendrix CW, Andrade A, Bumpus NN, Kashuba A, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I et al..  2015.  Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine after Directly Observed Dosing in Healthy Volunteers to establish Adherence Benchmarks (HPTN 066).. AIDS research and human retroviruses. Abstract
Herold BC, Dezzutti CS, Richardson BA, Marrazzo J, Mesquita PMM, Carpenter C, Huber A, Louissaint N, Marzinke MA, Hillier SL et al..  2014.  Antiviral Activity of Genital Tract Secretions following Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1.. Journal of acquired immune deficiency syndromes (1999). Abstract
K
Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN et al..  2015.  A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.. AIDS (London, England). Abstract
L
Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, Donnell D, Thomas KK, Hendrix CW, Marzinke MA et al..  2015.  Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.. The Journal of infectious diseases. 211(8):1211-8. Abstract
Lund JM, Broliden K, Pyra MN, Thomas KK, Donnell D, Irungu E, Muwonge TR, Mugo N, Manohar M, Jansson M et al..  2017.  Correction for Lund et al., HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.. Journal of virology. 91(3)
Lund JM, Broliden K, Pyra MN, Thomas KK, Donnell D, Irungu E, Muwonge TR, Mugo N, Manohar M, Jansson M et al..  2016.  HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.. Journal of virology. 90(21):9855-9861. Abstract
M
Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L et al..  2015.  Tenofovir-based preexposure prophylaxis for HIV infection among African women.. The New England journal of medicine. 372(6):509-18. Abstract
Marzinke MA, Clarke W, Wang L, Cummings V, Liu T-Y, Piwowar-Manning E, Breaud A, Griffith S, Buchbinder S, Shoptaw S et al..  2013.  Nondisclosure of HIV Status in a Clinical Trial Setting: Antiretroviral Drug Screening Can Help Distinguish Between Newly Diagnosed and Previously Diagnosed HIV Infection.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Abstract
N
Noguchi LM, Montgomery ET, Biggio JR, Hendrix CW, Bogen DL, Hillier SL, Dai JY, Piper JM, Marzinke MA, Dezzutti CS et al..  2016.  Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical Tenofovir.. Antimicrobial agents and chemotherapy. 60(9):5616-5619. Abstract
P
Piwowar-Manning E, Fogel JM, Laeyendecker O, Wolf S, Cummings V, Marzinke MA, Clarke W, Breaud A, Wendel S, Wang L et al..  2014.  Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening.. HIV clinical trials. 15(2):62-8. Abstract
Piwowar-Manning E, Fogel JM, Richardson P, Wolf S, Clarke W, Marzinke MA, Fiamma A, Donnell D, Kulich M, Mbwambo JKK et al..  2015.  Performance of the fourth-generation Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern Africa.. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 62:75-9. Abstract
S
Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL et al..  2017.  Characterization of HIV seroconverters in a TDF/FTC PrEP study: HPTN 067/ADAPT.. Journal of acquired immune deficiency syndromes (1999). Abstract